Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

346.38 +1.38 (+0.40%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 261,264
Open 342.37
Bid (Size) 341.00 (160)
Ask (Size) 352.00 (40)
Prev. Close 345.00
Today's Range 341.52 - 351.39
52wk Range 196.45 - 385.22
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Stocks to Buy in February ↗
These three stocks appear to be poised for strong performances in 2026. 
Via The Motley Fool
Topics Artificial Intelligence
BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini Trend Template and Strong Growth Scan ↗
Via Chartmill

Performance

YTD
+11.4%
+11.4%
1 Month
+8.1%
+8.1%
3 Month
+11.1%
+11.1%
6 Month
+13.8%
+13.8%
1 Year
+55.1%
+55.1%

More News

Read More
News headline image
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
From BeOne Medicines Ltd.
Via Business Wire
News headline image
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Where BeOne Medicines Stands With Analysts ↗
Via Benzinga
News headline image
BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features ↗
Via Benzinga
News headline image
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗
Via Investor's Business Daily
Topics Economy Government
News headline image
Analyst Expectations For BeOne Medicines's Future ↗
Via Benzinga
News headline image
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans ↗
Via Benzinga
News headline image
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines to Present at Upcoming Investor Conferences
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Investor Exits $5.5 Million Perpetua Resources Stake Amid Stock's 150% Rally ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6
From BeOne Medicines Ltd.
Via Business Wire
News headline image
What's Going On With Summit Therapeutics Stock On Monday? ↗
Via Benzinga
News headline image
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
From BeOne Medicines Ltd.
Via Business Wire
News headline image
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗
Via Investor's Business Daily
Topics Government

Frequently Asked Questions

Is BeOne Medicines Ltd. - American Depositary Shares publicly traded?
Yes, BeOne Medicines Ltd. - American Depositary Shares is publicly traded.
What exchange does BeOne Medicines Ltd. - American Depositary Shares trade on?
BeOne Medicines Ltd. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BeOne Medicines Ltd. - American Depositary Shares?
The ticker symbol for BeOne Medicines Ltd. - American Depositary Shares is ONC on the Nasdaq Stock Market
What is the current price of BeOne Medicines Ltd. - American Depositary Shares?
The current price of BeOne Medicines Ltd. - American Depositary Shares is 346.38
When was BeOne Medicines Ltd. - American Depositary Shares last traded?
The last trade of BeOne Medicines Ltd. - American Depositary Shares was at 02/03/26 04:00 PM ET
What is the market capitalization of BeOne Medicines Ltd. - American Depositary Shares?
The market capitalization of BeOne Medicines Ltd. - American Depositary Shares is 419.49B
How many shares of BeOne Medicines Ltd. - American Depositary Shares are outstanding?
BeOne Medicines Ltd. - American Depositary Shares has 419B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.